Table 2 Examples of peptides in different clinical trials and their indications
From: Therapeutic peptides: current applications and future directions
Clinical trial phase | Peptide name | Indication(s) for investigation |
|---|---|---|
IV | Avexitide500 | Hypoglycemia |
Calcitonin gene-related peptide501 | Migraine | |
Corticorelin502 | Brain swelling; brain neoplasms | |
Leptin503 | Lipodystrophy; obesity | |
Thymalfasin504 | Liver Cirrhosis; Sepsis | |
III | Diabetic foot ulcers | |
Albusomatropin507 | Growth hormone deficiency | |
Anamorelin508 | Cachexia; lung cancer non-small cell cancer | |
G17DT509 | Various forms of cancer | |
Insulin peglispro510 | Diabetes mellitus | |
Lenomorelin511 | Malignancies | |
Selepressin512 | Shock; septic | |
Somapacitan513 | Adult growth hormone deficiency | |
Taspoglutide514 | Type 2 diabetes mellitus | |
Thymosin beta-4515 | Dry eye syndrome | |
Tirzepatide516 | Type 2 diabetes mellitus | |
Ularitide517 | Decompensated heart failure | |
Vapreotide518 | Gastric varices; oesophageal haemorrhage; portal hypertension; esophageal varices | |
Vosoritide519 | Achondroplasia | |
Zoptarelin doxorubicin520 | Endometrial cancer; prostate cancer | |
II | Angiotensin 1-7521 | Miscellaneous Peripheral Blood Cell Abnormalities |
Bombesin522 | Prostate cancer | |
Cenderitide310 | Heart failure | |
Deslorelin523 | Puberty; precocious | |
Gastric inhibitory polypeptide524 | Type 2 diabetes mellitus | |
MK-3207525 | Migraine | |
Olcegepant526 | Migraine Disorders | |
Pancreatic Polypeptide527 | Type 1 diabetes | |
Peptide YY (3-36)528 | Metabolic disease; obesity | |
Pirnabine529 | Chronic idiopathic constipation | |
Somatoprim530 | Acromegaly | |
Somatropin pegol531 | Growth hormone deficiency | |
Thyrotropin532 | Benign nontoxic and toxic goiter; goiter; nodular | |
TT-232533 | Renal cell adenocarcinoma | |
I | BPI-3016534 | Type 2 diabetes mellitus |
NBI-6024535 | Type 1 diabetes mellitus | |
Many more… |  |
